OptumRx Arbitration Award Vacated: Judge Tosses $48 Million UNA Win as Procured by Fraud

A federal judge in Jacksonville has vacated, in full, the roughly $48 million arbitration award that prescription drug-discount marketer United Networks of America (UNA) won against OptumRx, holding that the award was procured by fraud because UNA's story about acquiring a competitor's business was "a lie." The OptumRx arbitration award vacated by Senior U.S. District Judge Timothy J. Corrigan, in an order unsealed on October 2, 2026, is one of the rare cases in which a court has set aside an award under the first and narrowest ground of the Federal Arbitration Act (FAA), and it ends, at least for now, a commission dispute that began more than a decade ago.

The case is OptumRx PBM of Illinois, Inc. v. United Networks of America, Inc., No. 3:23-cv-01308, in the U.S. District Court for the Middle District of Florida. Law360 reported the ruling on October 5 and put the award at $48 million; OptumRx's counsel, Gibson Dunn, described it as "nearly $50 million." The difference most likely reflects how the figure is counted, and the order itself was not publicly readable at the time of writing.

OptumRx arbitration award vacated: what the court decided

Judge Corrigan granted OptumRx's petition and vacated the award in its entirety. According to the passages quoted by Gibson Dunn, the court found that OptumRx "carried its burden" to show the "award was procured by…fraud," the language of 9 U.S.C. § 10(a)(1). The court's central factual finding was blunt: UNA's account of how it had acquired the discount card business of National Benefit Builders, Inc. (NBBI) was "a lie."

The court did not treat the fraud as a single false statement. It wrote that "the weight of the evidence points clearly and convincingly to fraudulent conduct by UNA," and that the timeline showed "not only that UNA withheld documents and lied in the arbitration," but also a broader pattern: after the supposed acquisition, UNA and NBBI "were still negotiating and drafting other agreements, under which NBBI would own its claims," which the court called "entirely inconsistent" with what the two companies had told OptumRx.

That last finding matters doctrinally. A court asked to vacate for fraud is not supposed to retry the merits. What it may do is decide whether the party that won the award obtained it through fraud the losing side could not reasonably have exposed in the arbitration. Withheld documents that later surface are the classic route to that showing, and the court's emphasis on documents UNA "withheld" signals that the evidence that sank the award was not in front of the arbitrator.

Why was the OptumRx arbitration award vacated?

The award was vacated because the court found, by clear and convincing evidence, that UNA won it by misrepresenting a December 2013 acquisition and withholding documents that would have exposed the misrepresentation. That finding satisfies § 10(a)(1) of the FAA, which allows a court to vacate an arbitral award "where the award was procured by corruption, fraud, or undue means."

The commercial background explains why the acquisition mattered so much. UNA markets prescription drug discount card programs directly to consumers and earns per-claim commissions when pharmacy claims run through a pharmacy benefit manager (PBM). Under an agreement OptumRx executed on December 10, 2013, OptumRx agreed to pay UNA a higher per-claim commission rate and to extend that rate to any discount card business UNA later acquired. OptumRx separately had its own contract with NBBI, a UNA competitor, at a lower rate.

Eight days later, according to OptumRx's pleadings in a parallel Colorado case, UNA and NBBI's principals told OptumRx that UNA had "acquired" NBBI's discount card programs effective December 17, 2013, and that NBBI's claims should now be paid at the UNA rate. If the acquisition was real, every NBBI claim moved onto the richer UNA schedule. If it was not, the "acquisition" was simply a way to reprice NBBI's book of business at OptumRx's expense. Judge Corrigan concluded it was the latter.

How much was the UNA award, and how did it come about?

The award was approximately $48 million (described by OptumRx's counsel as nearly $50 million), issued on October 5, 2023, by a single arbitrator, Paul E. Risner, after a proceeding that had been pending for more than seven years. UNA filed its demand for arbitration on May 26, 2016, with the American Health Law Association (AHLA, then the American Health Lawyers Association), a health care dispute-resolution forum rather than the American Arbitration Association (AAA) or JAMS.

The final evidentiary hearing opened on June 12, 2023, and ran six days. The record closed on September 6, 2023, and under the AHLA rules the arbitrator had 30 days to rule, which produced the October 5 award. The award text, as indexed by Jus Mundi, shows that the respondents (OptumRx and its affiliate Catamaran PBM of Colorado) had argued fraud in the arbitration and that the arbitrator rejected that defense, treating the refusal to pay as a breach of the agreement and upholding contractual late-payment charges as neither excessive nor punitive.

That sequence is what makes the vacatur notable. The arbitrator heard a fraud argument and rejected it. The district court later found fraud anyway. The two findings are reconcilable only because, on the court's account, the critical evidence was withheld in the arbitration and surfaced afterward.

Timeline: from a 2013 commission deal to a 2026 vacatur

Date	Event
Dec. 10, 2013	OptumRx executes the UNA agreement: higher per-claim commission, extended to businesses UNA acquires
Dec. 17, 2013	Claimed effective date of UNA's "acquisition" of NBBI's discount card programs
May 26, 2016	UNA files its demand for arbitration with the AHLA
Aug. 21, 2018	Stipulated protective order entered in the arbitration
Mar. 30, 2021	Arbitrator issues a supplemental finding
Apr. 24, 2023	Arbitrator issues an interim order
June 12, 2023	Six-day final hearing begins before arbitrator Paul E. Risner
Sept. 6, 2023	Record closes
Oct. 5, 2023	Final award for UNA, about $48 million
Nov. 3, 2023	OptumRx entities petition the M.D. Fla. to vacate under 9 U.S.C. § 10 (No. 3:23-cv-01308)
2023	OptumRx sues NBBI and three individuals in the District of Colorado (No. 1:23-cv-03020)
Jan. 5, 2024	UNA opposes vacatur and cross-moves to confirm the award, or for partial vacatur
Mar. 15, 2024	OptumRx opposes UNA's cross-motion to confirm
Apr. 29, 2024	Florida court grants an unopposed motion for a temporary stay
2024	Colorado magistrate judge finds probable cause under the crime-fraud exception and orders privileged documents produced
Oct. 2, 2026	Judge Corrigan's order vacating the award in full is unsealed
Oct. 5, 2026	Law360 reports the $48 million award "tossed for fraud"

The Colorado case that supplied the evidence

The Florida petition did not proceed in isolation. In 2023 OptumRx PBM of Illinois sued NBBI and three individuals, Raymond J. Marszalowicz, Kevin Faherty and Barry J. Forester, in the U.S. District Court for the District of Colorado, alleging that the NBBI "acquisition" was a scheme designed to mislead OptumRx into applying UNA's higher commission schedule to NBBI claims. One allegation in that complaint has a modern ring: minutes after OptumRx asked for documentary proof of the acquisition, an attorney for the defendants allegedly downloaded a template purchase agreement from a public website.

In 2024, U.S. Magistrate Judge N. Reid Neureiter found probable cause to believe the defendants had used counsel in furtherance of fraud and applied the crime-fraud exception, ordering production of documents that would otherwise have been privileged. Law360 headlined that ruling "No Privilege For Drug Discount Co. Accused Of Faking Deal." The Florida order's description of post-"acquisition" drafts under which "NBBI would own its claims" is exactly the kind of internal document that a crime-fraud ruling tends to pry loose.

For practitioners, the lesson is procedural rather than doctrinal. Arbitration offers limited discovery, and a party that suspects fraud may get far better access to evidence in a parallel lawsuit against non-signatories than it ever had in the arbitration. Here, the Colorado case appears to have been the engine; the Florida vacatur was the payoff.

Can a court vacate an arbitration award for fraud?

Yes, but only on a narrow showing. Section 10(a) of the FAA lists four grounds for vacatur, and the Supreme Court held in Hall Street Associates, L.L.C. v. Mattel, Inc., 552 U.S. 576 (2008), that §§ 10 and 11 provide the exclusive grounds for vacating or modifying an award on expedited review under the Act. Fraud is the first listed ground, and it is not a back door to relitigating credibility.

In the Eleventh Circuit, which covers Florida, the governing test comes from Bonar v. Dean Witter Reynolds, Inc., 835 F.2d 1378 (11th Cir. 1988). To vacate for fraud, the challenger must show:

1. clear and convincing evidence of fraud;
2. that the fraud materially relates to an issue involved in the arbitration; and
3. that due diligence would not have prompted discovery of the fraud during or before the arbitration.

In Bonar itself, the court vacated a punitive damages award because an expert witness had lied about his credentials. The OptumRx ruling tracks all three prongs. The court said the evidence pointed "clearly and convincingly" to fraud (prong one); the acquisition was the entire basis for applying UNA's commission rate to NBBI claims (prong two); and the court's focus on withheld documents speaks to prong three, since a party cannot be faulted for failing to find what its opponent concealed.

What is the test for vacating an arbitration award procured by fraud?

Most federal circuits apply a test close to Bonar's: clear and convincing proof, a material connection to the issues decided, and fraud that was not discoverable with due diligence before or during the arbitration. The third prong is usually decisive. If the losing party had the facts, or could have found them, and simply failed to persuade the arbitrator, courts treat the challenge as an impermissible attack on the merits.

How rare is a ruling like the OptumRx arbitration award vacated in Florida?

Very. The OptumRx arbitration award vacated in Jacksonville stands out because courts routinely describe vacatur as available only in exceptional cases, and the run of recent decisions makes the point. In late September, a Los Angeles federal judge refused to vacate a $4.25 million FINRA award against J.P. Morgan Securities despite calling the bank's objections "serious," observing that federal courts "rarely vacate arbitration awards." Days earlier, a court left standing an arbitration award involving Eric Schmidt after rejecting an argument that federal law kept the dispute out of arbitration. Those challenges attacked the arbitrators' reasoning or their authority to decide. The OptumRx challenge attacked how the award was obtained, which is the one category of complaint the FAA treats as a reason to set aside an award regardless of whether the arbitrator reasoned correctly.

Gibson Dunn itself called the order "rare," and the description is fair: a full vacatur of an eight-figure award on § 10(a)(1) grounds, after an arbitrator had already rejected a fraud defense, is an outlier.

Ground (9 U.S.C. § 10(a))	What the challenger must show	How often it succeeds
(1) Corruption, fraud or undue means	Clear and convincing proof; materiality; not discoverable by due diligence	Rarely; usually needs new evidence
(2) Evident partiality or corruption of arbitrators	Undisclosed relationships or bias a reasonable person would see	Occasionally, mostly disclosure failures
(3) Arbitrator misconduct	Refusal to postpone or hear pertinent evidence, prejudicing rights	Rarely
(4) Exceeding powers	Arbitrator went beyond the submission or the contract	Occasionally; "manifest disregard" contested

Can UNA appeal the order vacating the award?

Yes. Under 9 U.S.C. § 16(a)(1)(E), an appeal may be taken from an order vacating an award, so UNA may seek review in the U.S. Court of Appeals for the Eleventh Circuit. No notice of appeal had been reported as of October 6, 2026. On appeal, the court of appeals reviews the district court's legal conclusions de novo and its findings of fact, including a finding of fraud made on the evidentiary record, for clear error, which is a difficult standard for UNA to overcome on the "lie" finding.

What happens to the underlying commission claims is less certain. Section 10(b) of the FAA permits a court that vacates an award to direct a rehearing where the time for the award has not expired, and the reported description of the order as concluding the "decade-long dispute" suggests no rehearing was ordered. Neither the Gibson Dunn release nor the Law360 report indicates whether UNA retains any claim for commissions that would be owed on UNA's own (non-NBBI) business, and that point should be read in the order once it is available.

The timeline also illustrates a trap for award challengers. Section 12 of the FAA requires notice of a motion to vacate to be served within three months after the award is filed or delivered. OptumRx's petition was filed on November 3, 2023, 29 days after the October 5 award, well inside that window, even though much of the evidence that ultimately decided the case appears to have emerged later through the Colorado litigation.

What it means for mass arbitration

The OptumRx case is a two-party commercial dispute, not a mass arbitration, but its doctrine travels directly into the mass arbitration setting, where respondents increasingly argue that claimant pools are padded with people who never used the product, never agreed to the terms or never existed.

• For respondents facing mass filings. The ruling confirms that fraud in procuring an award is a live vacatur ground even after an arbitrator rejects a fraud defense, but only with clear and convincing proof and evidence that could not have been obtained in the arbitration. Process tools such as the Affirmation Requirement in the AAA's mass arbitration rules and front-end Claimant Vetting are still a far better investment than post-award litigation, because they put false statements on the record before an award issues.
• For claimants' counsel. Counsel who certify claimant information carry the risk. An award obtained on fabricated eligibility facts is exposed to vacatur under § 10(a)(1), and the Colorado crime-fraud ruling is a reminder that communications with counsel lose privilege when they further the fraud.
• For drafters. Narrow discovery is one of arbitration's selling points, but it cuts both ways. Parties that want protection against concealed evidence can draft document-exchange obligations and certification requirements into the clause, and can preserve the right to pursue non-signatories in court.
• For PBMs and health care counterparties. Commission and rebate contracts that extend favorable rates to "acquired" businesses invite exactly this dispute. Verification rights, a definition of "acquisition," and a documentary-proof condition before re-rating claims would have narrowed the fight considerably.
• For providers. The AHLA, like the AAA and JAMS, cannot police document production beyond what the arbitrator orders. The case will feed the argument that high-value arbitrations need firmer disclosure obligations.

Who are the parties?

United Networks of America describes itself as a "value-added healthcare products and services" provider that administers and markets prescription drug discount card programs directly to consumers. OptumRx, part of UnitedHealth Group's Optum business, is one of the largest PBMs in the United States and provides pharmacy benefit management and claims-processing services to health plan sponsors and other payors. The petitioners in Florida were OptumRx PBM of Illinois, Inc. and an affiliate; the arbitration caption also named Catamaran PBM of Colorado, the PBM OptumRx's parent acquired in 2015. Gibson Dunn represented OptumRx.

FAQ

Why was the OptumRx arbitration award vacated?

Judge Corrigan found that UNA procured the award by fraud: its claimed December 2013 acquisition of NBBI's discount card business was "a lie," and UNA withheld documents in the arbitration that would have shown it.

How much was the UNA arbitration award against OptumRx?

About $48 million, as reported by Law360; OptumRx's counsel described it as nearly $50 million. The award was issued on October 5, 2023, and has now been vacated in full.

Can a court vacate an arbitration award for fraud?

Yes. 9 U.S.C. § 10(a)(1) allows vacatur where an award was "procured by corruption, fraud, or undue means," but the challenger must prove fraud by clear and convincing evidence, show it was material, and show it could not have been discovered with due diligence during the arbitration.

Can UNA appeal?

Yes. 9 U.S.C. § 16(a)(1)(E) allows an appeal from an order vacating an award, which would go to the Eleventh Circuit. No appeal had been reported as of October 6, 2026.

What does the OptumRx ruling mean for mass arbitration?

It shows that awards built on false facts can be undone after the fact, which strengthens respondents' hand against fabricated or ineligible claims, but the high proof burden means claimant vetting and affirmations before the award remain the practical safeguard.

This article is analysis of public reporting and court records, not legal advice. The vacatur order was not publicly readable when this was written; quotations are taken from the excerpts published by counsel and press.